YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Inhibrx Biosciences, Inc. (NASDAQ:INBX) delivered the kind of clinical update that would normally be expected to get investors' attention. Its experimental cancer drug INBRX-106, combined with Merck's Keytruda, produced a confirmed respons…
Mark Lappe, Chief Executive Officer, purchased 25,000 shares of Inhibrx Biosciences, Inc. (NASDAQ:INBX) on September 8, 2026. SEC Form 4 filing. Transaction summary Metric Value Shares purchased 25,000 Transaction value $2.6 million Post-t…
(RTTNews) - "The market is a device for transferring money from the impatient to the patient." - Warren Buffett. Successful investing often comes down to patience, conviction, and the ability to stay the course through market fluctuations.…
Inhibrx Biosciences, Inc. (NASDAQ:INBX) is one of the best small cap stocks to buy for 10x potential. Inhibrx Biosciences, Inc. (NASDAQ:INBX) announced on May 11 positive interim results from the randomized, first-line Phase 2 portion of t…
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Merck (NYSE:MRK) is expanding clinical work around KEYTRUDA through…
Inhibrx Biosciences releases positive preliminary results from its trial of a new head and neck cancer treatment. Continue Reading
Shares of Inhibrx Biosciences INBX rallied 36.9% on Wednesday. The massive surge was triggered by encouraging updated interim data from INBX’s phase I/II study evaluating ozekibart (INBRX-109) in combination with the chemotherapy regimen,…
Market Catalysts Host Julie Hyman tracks several of the day's top trending stock tickers, including AT&T's (T) wireless subscriber growth, Bloomberg reporting T-Mobile (TMUS) is in talks to merge with Deutsche Telekom (DTE.DE, DTEGY), Adob…
[Wall Street New York stock exchange stock market] alexsl Inhibrx Biosciences (INBX [https://seekingalpha.com/symbol/INBX]) traded higher on Wednesday after Stifel launched its coverage of the cancer drug developer with a Buy recommendatio…
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Jefferies upgraded Deere (DE) to Hold from…
SAN DIEGO, March 19, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the fourth quarter and fiscal year 2025. Following the completion of the sale of INBRX-101…
March S&P 500 E-Mini futures (ESH26) are trending down -0.53% this morning as Treasury yields continued to rise after another surge in oil prices stoked concerns that the Middle East conflict would drive inflation higher. The 10-year T-not…
(RTTNews) - Inhibrx Biosciences, Inc. (INBX), a clinical-stage biopharmaceutical company, is advancing its INBRX-106 and Ozekibart programs, with key milestones expected next year. INBRX-106 is a specially designed drug that activates a pr…
(RTTNews) - Inhibrx Biosciences, Inc. (INBX), a clinical-stage biopharmaceutical company, reported its third-quarter 2025 financial results and highlighted the upcoming events to watch in the coming months. The company's lead drug candidat…
SAN DIEGO, Nov. 14, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the third quarter of 2025. Following the completion of the sale of INBRX-101 (the "101 Tran…
By John Vandermosten, CFA NASDAQ:LGND READ THE FULL LGND RESEARCH REPORT Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) reported outstanding results for its third quarter, with revenues almost double our estimates and adjusted core earnings pe…
(RTTNews) - Risk runs high, but so does the upside. Biotech investing thrives on bold bets and breakthrough data. On October 30, 2025, a wave of clinical-stage and commercial biopharma stocks surged to new 52-week highs, driven by breakthr…
(RTTNews) - Biotech stocks led the after-hours charge on Thursday, with Inhibrx Biosciences (INBX) skyrocketing over 81% on positive Phase 2 trial results in chondrosarcoma. Femasys (FEMY), Cingulate (CING), and Community Health Systems (C…
(RTTNews) - Biotech stocks surged in after-hours trading on Wednesday, October 22, led by Ventyx Biosciences, which soared over 88% on positive Phase 2 data. A mix of earnings updates, clinical news, and investor interest lifted several na…
(RTTNews) - Inhibrx Biosciences Inc. (INBX) has a key catalyst to watch in October involving one of its clinical drug candidates, Ozekibart. Ozekibart, formerly known as INBRX-109, is a precision-engineered, tetravalent death receptor 5 (D…
* Inhibrx Biosciences press release [https://seekingalpha.com/pr/20200152-inhibrx-reports-second-quarter-2025-financial-results] (NASDAQ:INBX [https://seekingalpha.com/symbol/INBX]): Q2 GAAP EPS of -$1.85. * Revenue of $1.3M. * MORE ON INH…
SAN DIEGO, Aug. 13, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the second quarter of 2025. Following the completion of the sale of INBRX-101 (the "101 Tra…
Ligand Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 84. Continue Reading View Comments
A Relative Strength Rating upgrade for Liquidia shows improving technical performance. Will it continue? Continue Reading View Comments
A Relative Strength Rating upgrade for Arcutis Biotherapeutics shows improving technical performance. Will it continue? Continue Reading View comments
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Inhibrx Biosciences Inc (Symbol: INBX), where a total volume of 679 contracts has been traded thus far today, a contract…
SAN DIEGO, April 1, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company with two programs in clinical-stage development, today announced the departure of Dr…
Inhibrx Biosciences (NASDAQ:INBX) Full Year 2024 Results Key Financial Results Net income: US$1.69b (up from US$241.4m loss in FY 2023). EPS: US$114 (up from US$20.48 loss in FY 2023). INBX Products In Clinical Trials Phase II: 2.NasdaqGS:…
SAN DIEGO, March 17, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the fourth quarter and fiscal year 2024. Following the completion of the sale of INBRX-101…
Inhibrx Biosciences (INBX) late Tuesday released preliminary safety and efficacy data from phase 1 t PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
SAN DIEGO, Jan. 21, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced p…
SAN DIEGO, Jan. 13, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. ("Inhibrx" or the "Company") (Nasdaq: INBX), a biopharmaceutical company with two programs in ongoing clinical trials, today announced it entered into a loan and security a…
Key Insights Given the large stake in the stock by institutions, Inhibrx Biosciences' stock price might be vulnerable to their trading decisions A total of 7 investors have a majority stake in the company with 50% ownership Insiders have b…
SAN DIEGO, Nov. 14, 2024 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx Biosciences" or the "Company") today reported financial results for the third quarter of 2024. Following the completion of the sale of INBRX-101 by…
SAN DIEGO, Nov. 4, 2024 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a biopharmaceutical company with two programs in ongoing clinical trials and a strong emerging pipeline, is pleased to announce…
On September 11, 2024, Kristiina Vuori, Director at Inhibrx Biosciences Inc (NASDAQ:INBX), acquired 6,636 shares of the company, as reported in a recent SEC Filing. Following this transaction, the insider now directly owns 13,776 shares of…